Contrast-enhanced transrectal ultrasonography for the detection of diffuse prostate cancer

Gao, Yong; Liao, Xin-Hong; LiZhi, Lu; Wang, L.; Ma, Yun; Qin, Hao; Xue, Yan; Guo, Peng

doi:10.1016/j.crad.2015.11.013

Cited by 6 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gao et al compared the diagnostic accuracy of CEUS versus greyscale TRUS with colour Doppler and noticed that CEUS can be character-ized with higher diagnostic accuracy than diffuse PCa. Detection of diffuse PCa without an obvious focal mass identified in TRUS or clinical examination may help detect patients who do not need a repeat biopsy [13]. Koh et al compared CEUS guided biopsy and sonoelastography guided biopsy.…”

Section: Multiparametric Ultrasonographymentioning

confidence: 99%

Elastography in prostate gland imaging and prostate cancer detection

Tyloch

Adamowicz

et al. 2018

Med Ultrason

View full text Add to dashboard Cite

Transrectal prostate biopsies under ultrasonography guidance remain the gold standard for the detection of prostate cancer (PCa). Transrectal ultrasonography (TRUS), however, has a limited sensitivity in PCa detection. Prostate elastography (TRES) increases the sensitivity of a TRUS examination. Therefore, the aim of this review is to discuss the usefulness of TRES in prostate gland imaging for the diagnosis and management of prostate cancer based on published literature. The advantages of transrectal elastography were analysed in the context of better diagnostic performance provided by this method. TRES provides additional information for the detection and biopsy guidance concerning prostate cancer, enabling a significant reduction in the number of biopsies.

show abstract

Section: Multiparametric Ultrasonographymentioning

confidence: 99%

Elastography in prostate gland imaging and prostate cancer detection

Tyloch

Adamowicz

et al. 2018

Med Ultrason

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Hence, the new method of contrast-enhanced ultrasound (CEUS) is being currently applied to differentiate some lesions that are hard to see [ 21 ]. The CEUS is thought to improve the visibility of focal lesions in organs [ 21 , 22 , 23 ]. Therefore, as a novel imaging technique, contrast-enhanced ultrasound (CEUS) may dynamically recognize the blood perfusion of vascularity, particularly feeding micro neovascularity linked with tumor.…”

Section: Introductionmentioning

confidence: 99%

Comparative Assessment of Different Ultrasound Technologies in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis

Alghamdi

Kernohan

et al. 2023

Cancers

View full text Add to dashboard Cite

The present study aimed to assess the diagnostic test accuracy of different ultrasound scanning technologies in the detection of prostate cancer. A systematic search was conducted using the Cochrane Guidelines for Screening and Diagnostic Tests. We performed a systematic search in the international databases PubMed, Medline, Ovid, Embase and Cochrane Library. Searches were designed to find all studies that evaluated Micro-US, mpUS, SWE and CEUS as the main detection modalities for prostate cancer. This study was registered with Research Registry of systematic review and meta-analysis. The QUADAS-2 tool was utilized to perform quality assessment and bias analysis. The literature search generated 1376 studies. Of these, 320 studies were screened for eligibility, with 1056 studies being excluded. Overall, 26 studies with a total of 6370 patients met the inclusion criteria. The pooled sensitivity for grayscale, CEUS, SWE, Micro-US and mpUS modalities were 0.66 (95% CI 0.54–0.73) 0.73 (95% CI 0.58–0.88), 0.82 (95% CI 0.75–0.90), 0.85 (95% CI 0.76–0.94) and 0.87 (95% CI 0.71–1.03), respectively. Moreover, the pooled specificity for grayscale, CEUS, SWE, Micro-US and mpUS modalities were 0.56 (95% CI 0.21–0.90), 0.78 (95% CI 0.67–0.88), 0.76 (95% CI 0.65–0.88), 0.43 (95% CI 0.28–0.59) and 0.68 (95% CI 0.54–0.81), respectively. In terms of sensitivity, substantial heterogeneity between studies was detected (I2 = 72%, p = 0.000 < 0.05). In relation to specificity, extreme heterogeneity was detected (I2 = 93%, p = 0.000 < 0.05). Some studies proved that advanced ultrasound modalities such as mpUS, Micro-US, shear-wave elastography, contrast enhanced and micro-ultrasound are promising methods for the detection of prostate cancer.

show abstract

“…The quantitative indicators of time-intensity curve (TIC) are accurate for the identification of benign and malignant tumors in contrast-enhanced ultrasound (CEUS) imaging. 8,9 Studies have demonstrated that TIC is a reliable quantitative tool for diagnosing the benign and malignant prostate tumors. 10,11 In addition, it can be used to assess the aggressiveness of PCa and to predict PCa biopsy results.…”

Section: Introductionmentioning

confidence: 99%

<p>Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment</p>

Jiang-jun¹,

Zhao²,

Jiang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Some patients with prostate cancer (PCa) will experience biochemical recurrence (BCR) after treatment. Current researches have identified the influencing factors of BCR, but these factors are difficult to quantify and hence unable to accurately predict the BCR in PCa patients. Objective: To explore the value of contrast-enhanced ultrasound (CEUS) indicators in predicting the BCR after treatment by evaluating the association between them. Patients and Methods: In a retrospective cohort study, 157 PCa patients were recruited and received prostate specific antigen (PSA) measurement, CEUS, pathological classification, and immunohistochemistry after puncture biopsy. PCa patients with BCR were included in the recurrence group, while the remaining patients were included in the non-recurrence group after a 5-year follow-up. The clinical characteristics and CEUS indicators were compared between the two groups, and the multivariable COX regression was used for screening the influencing factors of BCR. Receiver operating characteristic (ROC) curves were used to analyze the value of potential factors in predicting BCR. The effect of the combined prediction model was explored to improve the accuracy of the prediction. Results: Twelve patients are lost during the follow-up period and the final analysis included 145 patients. The 5-year BCR rate of PCa patients was 27%, with 43 patients in the recurrence group and 102 patients in the non-recurrence group. Multivariate analysis showed that lymph node metastasis (P<0.001), distant metastasis (P<0.001), Gleason score (P<0.001), pretreatment PSA (P<0.001), treatment method (P<0.001), peak intensity (PI) (P=0.001), and time to peak (TTP) (P=0.003) were independent influencing factors for BCR after treatment. ROC analysis showed that the AUCs of all indicators in predicting BCR were not high (all <0.9). The combination of lymph node metastasis, Gleason score, pretreatment PSA, and treatment method can improve the predictive accuracy (AUC = 0.85), but the AUC was still under 0.9. The combined prediction model including CEUS time-intensity curve (TIC) indicators (PI and TTP) could accurately predict the BCR after treatment (AUC=0.953). The sensitivity and specificity were 93.02% and 88.24%, respectively. Conclusion:The prediction model including TIC indicators and common influencing factors can more accurately predict the BCR in PCa patients.

show abstract

Contrast-enhanced transrectal ultrasonography for the detection of diffuse prostate cancer

Cited by 6 publications

References 16 publications

Elastography in prostate gland imaging and prostate cancer detection

Elastography in prostate gland imaging and prostate cancer detection

Comparative Assessment of Different Ultrasound Technologies in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis

<p>Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment</p>

Contact Info

Product

Resources

About